drugset / Trial / NCT05756972
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
NaSingle-groupOpen-labelTreatment
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment.
Timeline
- Start
- 2023-06-26
- Primary completion
- 2024-09-13
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |